TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17148777

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTC group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No systemic chemotherapy (no-CT group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 28
Study: 12663594

Group type: EXPERIMENTAL
Intervention: Thyroid function tests (TSH, thyroxine, triiodothyronine) annually and TPO antibodies every 4 years
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Annual screening by serum TSH measurement
Number of subjects: 58
Study: 11177201

Group type: EXPERIMENTAL
Intervention: Protocol A: 1000 g of 58Fe-labelled formula (1.44 mg total Fe/1000 g) as six feeds over 24 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Protocol B: 1000 g of 58Fe-labelled formula (1.44 mg total Fe/1000 g) as two feeds/day on three consecutive days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference dose: Water solution with 57Fe and ascorbic acid
Number of subjects: 10
Study: 8848320

Group type: EXPERIMENTAL
Intervention: Shorter sterile technique (handwash of 30 s and double gloving)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Longer sterile technique (3 minute wash from fingertips to elbows and wearing a sterile gown and one pair of gloves)
Number of subjects: 46
Study: 1330470

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg/bid for 10.5 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3901660

Group type: EXPERIMENTAL
Intervention: ORS60 (Na+ 60 mmol/l)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Commercial low sodium glucose-electrolyte solution (sodium 35 mmol/l, glucose 3.5 milligrams)
Number of subjects: 66
Study: 29084918

Group type: EXPERIMENTAL
Intervention: Ontuxizumab (8 mg/kg) plus best supportive care
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 126
Study: 27353315

Group type: EXPERIMENTAL
Intervention: 8-session cue exposure therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 45
Study: 25809304

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fingolimod pooled (0.5 mg and 1.25 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23633161

Group type: EXPERIMENTAL
Intervention: Family-to-Family (FTF) education program
Number of subjects: 442

Group type: COMPARATOR
Intervention: Decliner population (those who declined RCT participation)
Number of subjects: 442
Study: 20886731

Group type: EXPERIMENTAL
Intervention: Spinal-epidural anesthesia (SEA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Epidural anesthesia (EA)
Number of subjects: 72
Study: 18813409

Group type: EXPERIMENTAL
Intervention: Open HS hemorrhoidectomy (n=22)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Closed HS hemorrhoidectomy (n=22)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Miligan Morgan hemorrhoidectomy (n=22)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ferguson hemorrhoidectomy (n=21)
Number of subjects: 87
Study: 15734619

Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5 mg atorvastatin
Number of subjects: 40
Study: 12783075

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined CRT and defibrillator device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Defibrillators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CRT)
Number of subjects: 0
Study: 10388298

Group type: EXPERIMENTAL
Intervention: Stroke unit care (SU)
Number of subjects: 14300

Group type: COMPARATOR
Intervention: General ward care (GW)
Number of subjects: 14300
Study: 8848472

Group type: EXPERIMENTAL
Intervention: NSAIDs (aspirin and ibuprofen)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 2049419

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intraperitoneal vancomycin/aztreonam
Number of subjects: 43
Study: 6338684

Group type: EXPERIMENTAL
Intervention: Continuous (150 to 200 cc/min) profound (4°C) topical hypothermia (Group A)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Identical topical hypothermia plus one initial 500 cc aortic root bolus of cold (4°C) hyperkalemic cardioplegic solution (Group B)
Number of subjects: 113
Study: 29396702

Group type: EXPERIMENTAL
Intervention: 1.5% FMX103
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 3% FMX103
Number of subjects: 232

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Both doses (1.5% and 3% FMX103)
Number of subjects: 232
Study: 28390209

Group type: EXPERIMENTAL
Intervention: Commercially available toothpaste Pronamel® for Children (n = 82)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Experimental plaque biofilm-loosening formula (PBF) toothpaste (n = 79)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Experimental Gentle Mint toothpaste (n = 78)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control: biotène® Fresh Mint Original toothpaste (n = 82)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control: biotène® Gentle Mint Gel toothpaste (n = 77)
Number of subjects: 239
Study: 24507462

Group type: EXPERIMENTAL
Intervention: Computerized Antithrombotic Risk Assessment Tool (CARAT) applied by GPs during consultations
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (standard care without CARAT)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: CARAT applied at baseline and repeated at 12 months
Number of subjects: 500
Study: 23753098

Group type: EXPERIMENTAL
Intervention: Interactive group education modules (2 sessions, 6 sessions each) on early feeding practices
Number of subjects: 698

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 698
Study: 20713865

Group type: EXPERIMENTAL
Intervention: Rasburicase (0.20 mg/kg/d intravenously days 1‐5)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d days 1 to 3 followed by oral allopurinol 300 mg/d days 3 to 5)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Allopurinol (300 mg/d orally days 1 to 5)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Rasburicase plus allopurinol
Number of subjects: 275

Group type: COMPARATOR
Intervention: Rasburicase, Rasburicase plus allopurinol, Allopurinol
Number of subjects: 275
Study: 18672777

Group type: EXPERIMENTAL
Intervention: Hewei Xiaopi Capsule (HXC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Domperidone (Control)
Number of subjects: 63
Study: 16809591

Group type: EXPERIMENTAL
Intervention: Experimental group (model substance abuse program)
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1370
Study: 15556742

Group type: EXPERIMENTAL
Intervention: Medical Assistants (MAs)
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Licensed Practical Nurses (LPNs)
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Registered Nurses (RNs)
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Guideline intervention
Number of subjects: 1221
Study: 11023622

Group type: EXPERIMENTAL
Intervention: Mailed educational intervention
Number of subjects: 813

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 813
Study: 9132125

Group type: EXPERIMENTAL
Intervention: diclofenac 0.1% unconserved eyedrops (DICun) pre- and postoperatively
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: diclofenac 0.1% conserved eyedrops (DICco) pre- and postoperatively
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DICun postoperatively
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DICun pre- and postoperatively, plus dexamethasone-21-dihydrogenphosphate 0.1% eyedrops (DEXA) postoperatively
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DEXA postoperatively
Number of subjects: 150
Study: 8508194

Group type: EXPERIMENTAL
Intervention: Vitamin B-complex supplementation (n = 22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 42
Study: 3306893

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31743602

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg and/or 100 mg daily (monotherapy)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg daily (add-on treatment)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study: 29279527

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5 mg/day)
Number of subjects: 67
Study: 27690320

Group type: EXPERIMENTAL
Intervention: Infertile men (normozoospermic)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Infertile men (asthenozoospermic, oligozoospermic, oligoasthenozoospermic)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Infertile men (oligozoospermic, oligoasthenozoospermic, asthenozoospermic)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fertile control
Number of subjects: 86
Study: 24965954

Group type: EXPERIMENTAL
Intervention: Oral health care using an oral moisture gel
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard oral health care
Number of subjects: 142
Study: 23093615

Group type: EXPERIMENTAL
Intervention: B vitamins supplementation (folate, B12, B6)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study: 20504306

Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (15 microg HA/strain/0.1-ml dose)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Adjuvanted vaccine (15 microg HA/strain/0.5-ml dose) administered intramuscularly
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Intradermal vaccine
Number of subjects: 795

Group type: COMPARATOR
Intervention: Adjuvanted vaccine
Number of subjects: 795
Study: 18839835

Group type: EXPERIMENTAL
Intervention: Generic meropenem (Mapenem)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Original meropenem (Meronem)
Number of subjects: 26
Study: 15812454

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg for infants and 20 mg for others)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11919304

Group type: EXPERIMENTAL
Intervention: PTCA alone
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: PTCA plus abciximab
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Stenting alone
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 2082
Study: 10334612

Group type: EXPERIMENTAL
Intervention: Experimental group received copies of their medical record progress notes and completed question lists for physician review.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group received health education sheets and completed suggestion lists for improving clinic care.
Number of subjects: 205
Study: 8951590

Group type: EXPERIMENTAL
Intervention: A‐type natriuretic peptide (ANP) infusion at 0.1 microgram/kg/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B‐type natriuretic peptide (BNP) infusion at 0.1 microgram/kg/min
Number of subjects: 0
Study: 2022158

Group type: EXPERIMENTAL
Intervention: Omeprazole, 10 mg every morning
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg every morning
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice a day
Number of subjects: 270
Study: 7038142

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (nephrectomy) and adjuvant active immunotherapy (bacillus Calmette‐Guerin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Historical controls treated with conventional methods (hormones, chemotherapy, and radiotherapy with or without nephrectomy)
Number of subjects: 20
Study: 29985724

Group type: EXPERIMENTAL
Intervention: KT without tension group (WTG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: KT tension group (TG)
Number of subjects: 54
Study: 31432434

Group type: EXPERIMENTAL
Intervention: tDCS over Broca's area
Number of subjects: 12
Study: 28905831

Group type: EXPERIMENTAL
Intervention: Goggles with side covers (Group A)
Number of subjects: 575

Group type: COMPARATOR
Intervention: No safety eyewear (Group B)
Number of subjects: 575
Study: 26325513

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 90

Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 90
Study: 25002195

Group type: EXPERIMENTAL
Intervention: Home exercise programme (aerobic training and muscle strength training) for 3 months, supervised by telephone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual activities (Control group)
Number of subjects: 41
Study: 22178484

Group type: EXPERIMENTAL
Intervention: Standard laparoscopic colectomy (SLC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic colectomy (SILC)
Number of subjects: 32
Study: 20810048

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2a (3 million units SC three times/week) + Ribavarin (1000 mg/day for weight ≤ 75kg; 1200 mg/day for weight > 75kg)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Interferon alpha 2b (3 million units SC three times/week) + Ribavarin (1000 mg/day for weight ≤ 75kg; 1200 mg/day for weight > 75kg)
Number of subjects: 310
Study: 17469684

Group type: EXPERIMENTAL
Intervention: Various approaches to QOL assessment (patient self‐report, caregiver proxy report, observational assessment by trained observers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dementia-specific measures of QOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic measures of QOL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical trials of pharmacotherapy for dementia
Number of subjects: 0
Study: 16096860

Group type: EXPERIMENTAL
Intervention: Superficial venous surgery (SVS)
Number of subjects: 32
Study: 12365884

Group type: EXPERIMENTAL
Intervention: OK-432 (Picibanil) sclerotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (observed for 6 months)
Number of subjects: 30
Study: 10414910

Group type: EXPERIMENTAL
Intervention: G-CSF administration on day +1 (group B)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: G-CSF administration on day +7 (group C)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No G-CSF (group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: G-CSF administration (both early and delayed)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: G-CSF administration (early vs delayed)
Number of subjects: 21
Study: 8528942

Group type: EXPERIMENTAL
Intervention: 3 MU of recombinant IFN‐alpha 2b 3 times a week for 6 months
Number of subjects: 22
Study: 2221302

Group type: EXPERIMENTAL
Intervention: Continuous application of alfentanil (0.023 mg/kg b.w./h) and midazolam (0.10 mg/kg b.w./h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Discontinuous application of midazolam (0.13 mg/kg b.w./h) with continuously given alfentanil (0.028 mg/kg b.w./h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous application of both substances
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both substances
Number of subjects: 30
Study: 6220415

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) and Massage
Number of subjects: 0
Study: 30790597

Group type: EXPERIMENTAL
Intervention: CDP-choline (500 mg) and galantamine (16 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31313549

Group type: EXPERIMENTAL
Intervention: Arbekacin sulphate 200 mg OD
Number of subjects: 162

Group type: COMPARATOR
Intervention: Vancomycin hydrochloride 1000 mg BD
Number of subjects: 162
Study: 27263074

Group type: EXPERIMENTAL
Intervention: Early palliative care involvement triggered by length of stay > 8 days
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Questionnaire burden assessment
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Participants' comments on intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study: 25532954

Group type: EXPERIMENTAL
Intervention: 400 μg capsaicin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 800 μg capsaicin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 500 mg ASA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 400 μg capsaicin + 500 mg ASA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 800 μg capsaicin + 500 mg ASA
Number of subjects: 15
Study: 22654196

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 164

Group type: COMPARATOR
Intervention: IRT (placebo)
Number of subjects: 164

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 164
Study: 18270808

Group type: EXPERIMENTAL
Intervention: Strong Healthy Women intervention
Number of subjects: 0
Study: 20599292

Group type: EXPERIMENTAL
Intervention: Calcipotriene plus nicotinamide 1.4%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinamide 1.4% alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcipotriene alone
Number of subjects: 0
Study: 16235180

Group type: EXPERIMENTAL
Intervention: 7-valent conjugate pneumococcal vaccine (CPV); 2 doses, 4 weeks apart
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 12442196

Group type: EXPERIMENTAL
Intervention: Constant load test at anaerobic lactate threshold (CTAT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Constant load test 10% above individual threshold (CT+10%)
Number of subjects: 11
Study: 9756018

Group type: COMPARATOR
Intervention: Systemic chemotherapy with mitomycin, mitoxanthrone and cisplatin (5 patients)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Celiac axis infusion regional chemotherapy with SpherexR microembolization (9 patients)
Number of subjects: 14
Study: 8147340

Group type: EXPERIMENTAL
Intervention: Immune milk (90 g daily for 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal product (control)
Number of subjects: 0
Study: 3197914

Group type: EXPERIMENTAL
Intervention: 2% butoconazole nitrate cream for 3 days
Number of subjects: 63

Group type: COMPARATOR
Intervention: 1% clotrimazole cream for 6 days
Number of subjects: 63
Study: 31231758

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) from beetroot juice (13.4 ± 1.6 mmol NO3‐)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) from beetroot juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (beetroot juice devoid of NO3‐)
Number of subjects: 12
Study: 29189290

Group type: EXPERIMENTAL
Intervention: Hypotension during surgery
Number of subjects: 9765

Group type: EXPERIMENTAL
Intervention: Hypotension on the remaining day of surgery
Number of subjects: 9765

Group type: EXPERIMENTAL
Intervention: Hypotension during the first four postoperative days
Number of subjects: 9765
Study: 27798330

Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate (WPI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soy-Dairy Protein Blend (PB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study: 24225332

Group type: EXPERIMENTAL
Intervention: TExT-MED (2 daily text messages for 6 months)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: TExT-MED
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: TExT-MED (Spanish speakers)
Number of subjects: 128
Study: 22431578

Group type: COMPARATOR
Intervention: Chlorthalidone (C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normokalemia (potassium 3.5-5.4 mmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperkalemia (potassium >5.4 mmol/L)
Number of subjects: 0
Study: 21094350

Group type: EXPERIMENTAL
Intervention: Primary PCI in patients presenting to PCI hospitals
Number of subjects: 3340

Group type: COMPARATOR
Intervention: Primary PCI in patients presenting to non-PCI hospitals
Number of subjects: 3340

Group type: EXPERIMENTAL
Intervention: Primary PCI in patients presenting with respiratory failure
Number of subjects: 3340

Group type: EXPERIMENTAL
Intervention: Primary PCI in patients presenting during off-work hours
Number of subjects: 3340

Group type: EXPERIMENTAL
Intervention: Primary PCI in patients with co-morbid conditions such as diabetes and heart failure
Number of subjects: 3340
Study: 18672740

Group type: EXPERIMENTAL
Intervention: Acupuncture at TH3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acupuncture at GB43
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acupuncture at H7
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acupuncture at ST44
Number of subjects: 10
Study: 15847970

Group type: EXPERIMENTAL
Intervention: Always using condoms at wave 2
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Self-reported STIs at wave 3
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Unprotected anal sex at wave 3
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Always requesting that partners use condoms at wave 2
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: IPV at wave 2
Number of subjects: 416
Study: 12898500

Group type: EXPERIMENTAL
Intervention: Mental Health Treatment Court (MHTC) with Assertive Community Treatment (ACT)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 235
Study: 11601016

Group type: EXPERIMENTAL
Intervention: Exogenous natural porcine pulmonary surfactant (150 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 24